510 related articles for article (PubMed ID: 25749412)
1. PIM kinase (and Akt) biology and signaling in tumors.
Warfel NA; Kraft AS
Pharmacol Ther; 2015 Jul; 151():41-9. PubMed ID: 25749412
[TBL] [Abstract][Full Text] [Related]
2. The survival kinases Akt and Pim as potential pharmacological targets.
Amaravadi R; Thompson CB
J Clin Invest; 2005 Oct; 115(10):2618-24. PubMed ID: 16200194
[TBL] [Abstract][Full Text] [Related]
3. Targeting PIM Kinases to Overcome Therapeutic Resistance in Cancer.
Toth RK; Warfel NA
Mol Cancer Ther; 2021 Jan; 20(1):3-10. PubMed ID: 33303645
[TBL] [Abstract][Full Text] [Related]
4. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
Chen K; Yang J; Li J; Wang X; Chen Y; Huang S; Chen JL
Oncotarget; 2016 Mar; 7(9):10073-89. PubMed ID: 26848623
[TBL] [Abstract][Full Text] [Related]
5. PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer.
Aziz AUR; Farid S; Qin K; Wang H; Liu B
Biomolecules; 2018 Feb; 8(1):. PubMed ID: 29401696
[TBL] [Abstract][Full Text] [Related]
6. PIM activity in tumours: A key node of therapy resistance.
Rebello RJ; Huglo AV; Furic L
Adv Biol Regul; 2018 Jan; 67():163-169. PubMed ID: 29111105
[TBL] [Abstract][Full Text] [Related]
7. [Drug resistance mediated by survival- and growth-promoting signaling pathways].
Fujita N
Gan To Kagaku Ryoho; 2009 Apr; 36(4):567-71. PubMed ID: 19381028
[TBL] [Abstract][Full Text] [Related]
8. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.
Schatz JH; Oricchio E; Wolfe AL; Jiang M; Linkov I; Maragulia J; Shi W; Zhang Z; Rajasekhar VK; Pagano NC; Porco JA; Teruya-Feldstein J; Rosen N; Zelenetz AD; Pelletier J; Wendel HG
J Exp Med; 2011 Aug; 208(9):1799-807. PubMed ID: 21859846
[TBL] [Abstract][Full Text] [Related]
9. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
Yang Q; Chen LS; Gandhi V
Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
[TBL] [Abstract][Full Text] [Related]
11. A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy.
Panchal NK; Sabina EP
Life Sci; 2020 Aug; 255():117866. PubMed ID: 32479955
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Pim kinases in multiple myeloma.
Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
[TBL] [Abstract][Full Text] [Related]
13. Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer.
Malone T; Schäfer L; Simon N; Heavey S; Cuffe S; Finn S; Moore G; Gately K
Pharmacol Ther; 2020 Mar; 207():107454. PubMed ID: 31836451
[TBL] [Abstract][Full Text] [Related]
14. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
15. A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target.
Rout AK; Dehury B; Parida SN; Rout SS; Jena R; Kaushik N; Kaushik NK; Pradhan SK; Sahoo CR; Singh AK; Arya M; Behera BK
Int J Biol Macromol; 2024 Jun; 270(Pt 1):132030. PubMed ID: 38704069
[TBL] [Abstract][Full Text] [Related]
16. The Pim kinases: new targets for drug development.
Swords R; Kelly K; Carew J; Nawrocki S; Mahalingam D; Sarantopoulos J; Bearss D; Giles F
Curr Drug Targets; 2011 Dec; 12(14):2059-66. PubMed ID: 21777193
[TBL] [Abstract][Full Text] [Related]
17. PIM kinases: From survival factors to regulators of cell motility.
Santio NM; Koskinen PJ
Int J Biochem Cell Biol; 2017 Dec; 93():74-85. PubMed ID: 29108877
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects.
Rathi A; Kumar D; Hasan GM; Haque MM; Hassan MI
Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129995. PubMed ID: 34455019
[TBL] [Abstract][Full Text] [Related]
19. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.
Blanco-Aparicio C; Carnero A
Biochem Pharmacol; 2013 Mar; 85(5):629-643. PubMed ID: 23041228
[TBL] [Abstract][Full Text] [Related]
20. Potential Pharmacological Inhibitors of Pim Kinase Under Clinical Trials.
Jeyapal GP; Chandrasekar MJN; Krishnasamy R; Selvaraj J; Mohammad M; Nanjan MJ
Anticancer Agents Med Chem; 2018; 18(8):1100-1114. PubMed ID: 29384063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
